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Abstract
Tumor microenvironment has complex effects on tumorigenesis and metastasis. However,
there is still a lack of comprehensive understanding of the relationship among molecular and
cellular characteristics in tumor microenvironment, clinical prognosis and
immunotherpy response. In this study, the immune and stromal (non-immune) signatures of
tumor microenvironment were integrated to identify novel subgroups of lung adenocarcinoma
by eigendecomposition and extraction algorithms of bioinformatics and machine learning, such
as non-negative matrix factorization and multitask learning. Tumors were classified into
4 groups according to the activation of immunity and stroma by novel signatures. The
4 groups had different mutation landscape, molecular, cellular characteristics and prognosis,
which have been validation in 6 independent data sets containing 1551 patients. High-immune
and low-stromal activation group links to high immunocyte infiltration, high
immunocompetence, low fibroblasts, endothelial cells, collagen, laminin, tumor mutation
burden, and better overall survival. We developed a novel model based on tumor
microenvironment by integrating immune and stromal activation, namely PMBT (prognostic
model based on tumor microenvironment). The PMBT showed the value to predict overall
survival and immunotherapy responses. We submitted an simple R package
(https://github.com/ZengZihang/PMBT) to enable any researcher to apply our novel immune,
stromal and PMBT scores.
Introduction
Lung cancer is the most frequent tumor, of which non-small cell lung cancer (NSCLC)
accounts for 80 percent (1, 2). Lung adenocarcinoma (LUAD) is well acknowledged for its
malignancy and morbidity rate among people, and exhibits diversity of gene mutations.
Normally, innate and required immunity are responsible for tumor cell distinguishment and
elimination in tumor immune microenvironment (3). With the discovery of immune checkpoint
inhibitors, such as programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) (4),
cytotoxic T-lymphocyte-associated protein 4 (CLTA-4), immunotherapy becomes a promising
method to treat LUAD (5). Nevertheless, immunotherapy only benefit ~16% LUAD patients for
long-term survival (6). It remains unsolved to deal with patients with therapeutic tolerance (7).
Tumor stroma (non-immune) was reported to be closely related to the progression, metastasis
and poor prognosis of tumors (8). However, the immune and stroma components of tumor
microenvironment (TME) are to be investigated. This study aimed to propose a new insight
and classification method to integrate both immune and stromal impacts on TME in LUAD.
TME is a very complex mixture, containing tumor cells, endothelial cells of blood and
lymphatic vessels, fibroblasts, immune cells and normal tissues (9). In the common analysis
such as gene chip and second generation sequencing, the results may be unstable due to the
influence of the TME, since the non-tumor characteristic signals are not identified. Therefore,
this study tried to identify the characteristic genes of TME by signal decomposition algorithm.
Non-negative matrix factorization (NMF) is a practical approach to decomposite matrix and
distract abstract characteristics among massive data sets, which is commonly exploited for
gene pattern recognition and computer vision in biomedical engineering (10, 11). Multitask
learning (MTL) is an inductive transfer method to improve predictive capability by learning
tasks in parallel while using shared representations (12, 13).
Integrating multi-omics data helps to achieve a comprehensive understanding in medical
research (14). Besides transcriptionomics analysis, genomics data were used to calculate the
tumor mutation burden (TMB) and frequency of single gene mutation in this study.
In general, we identified the 4 subgroups based on TME features in LUAD. Different
molecular, cellular characteristics, mutation landscape and prognosis were discovered in the 4
groups, which was validated in the 6 independent data sets containing 1551 patients. The flow
chart of this study was showed in Supplementary Fig. S1.
Materials and Methods
Data standardization and preprocessing
Six data sets containing transcriptome expression profile and clinical information of 1551
LUAD patients containing 1 train data set from TCGA-LUAD and the 5 validation data sets
from GEO database (Supplementary Table S1). Oligoexpression genes not expressed in most
samples were excluded from analysis. The high throughput transcriptome sequencing data
(TCGA-LUAD) implemented RNA-Seq by Expectation Maximization (RSEM) and log2(x+1)
standardization (15), and RNA profiling chip (GSE11969, GSE68465, GSE68571, GSE37745
and GSE50081) adopted robust multi-array average (RMA) standardization (16-22). All data
were normalization by Z-score and min-max methods to further analysis.
Non-Negative Matrix Factorization
Unsupervised low-dimensional microdissected feature was extracted from TME by NMF
method (23). The K number of NMF factors (K = 11) was determined by hierarchical clustering
of TCGA transcriptome data (Supplementary Fig. S2A). Primitive gene expression matrix was
decomposed into gene loading matrix and sample loading matrix through brunet methods after
2000 iterations (24). Top 100 weighted genes of each NMF factor were considered as
characteristic genes for subsequent enrichment analysis.
Calculating the Levels of Different Immune and Stromal Features in TME
TME related cell content was examined by MCPcounter (8 types of immune cells, endothelial
cells and fibroblasts, https://zenodo.org/record/61372), CIBERSORT (22 types of human
hematopoietic cells, http://cibersort.stanford.edu) and TIMER (6 types of immune cells,
https://cistrome.shinyapps.io/timer/) in each sample (25-27). The Pearson correlation analysis
of cell contents in different software was used to find robust results.
The single-sample gene set enrichment analysis (ssGSEA) for microarray and RNA-Seq
data was used to calculate the enrichment score of each sample based on different immunity
related and stroma related genes in TME (28). The production activity of interleukin-1,2,6,10
and IFN-γ was quantitatively calculated by ssGSEA using gene features from Gene Ontology
(GO, http://www.geneontology.org) (29). PD-1 signaling activation was calculated by Quigley’s
PD-1 related genes (30). The tumor-infiltrating lymphocytes (TIL) scores of hematoxylin and
eosin (H&E) sections from TCGA were obtained from previous study (31). The immune and
stromal scores were calculated by ssGSEA using Kosuke’s immune and stromal characteristic
genes (32) and Richard stromal characteristic genes (9).
ℓ2,1-Norm Regularized Multitask Learning
MTL was used to filter genes related to multiple traits. This method was beneficial for making
the results more sparse and robust by limit of ℓ2,1-norm regularization. MTL consists of
multiple linear regression sub-tasks containing NMF factor feature and TME cell relative
contents. By optimizing the ℓ1 and ℓ2 norm, a small number of genes with regression
coefficients in all subtasks were screened out. In this study, 5 subtasks were involved in MTL
including 2 immune and stromal NMF factor features, T cell, B cell, endothelial cell and
fibroblast abundance of MCPcounter. The code of MTL was based on MATLAB
(https://github.com/jiayuzhou/MALSAR).
GO Enrichment and Gene Set Enrichment Analysis
The GO enrichment included over-representation analysis (ORA) and gene set enrichment
analysis (GSEA) using WebGestalt tools (http://www.webgestalt.org/option.php) and R
clusterProfiler package (33, 34).
Different Gene Expression Analysis
Different gene expression (DGE) analysis was used to identify different expression genes
(DEGs) with significant difference at RNA level between the 2 classified phenotype, which was
realized by R limma package (35).
Mutation Analysis
LUAD mutation data were obtained from whole-exome sequencing files on Genomic Data
Commons website (https://portal.gdc.cancer.gov/repository). Mutation data were analyzed
using maftools package of R language (36).
Meta-Analysis
For meta-analysis, our prognostic effect of interest was overall survival (OS). Hazard ratio (HR)
integration of TME phenotypic groups with multiple data sets was accomplished using meta
package of R (https://cran.r-project.org/doc/Rnews/Rnews_2007-3.pdf). The fixed effect model
was used when there was no obvious heterogeneity among multiple data sets (I2 < 50%),
otherwise the random effect model was used.The HR and 95% confidence interval (CI) were
visualized in forest plot. The 3,5-year survival rates were calculated using a non-controlled
method. The standard error of survival rates were estimated as binary variables. The
calculation was as follows:
NsPtPtPSE /)1(*2^)t( 
where Pt is survival rate of time t, SE(Pt) is the standard error of Pt, and Ns is the number
of risk at time t. Non-controlled meta analysis was realized by Importing SE(Pt) and Pt into
Revman 5 software (https://community.cochrane.org/help/tools-and-software/revman-5).
Intercellular Communication Network
The intercellular communication networks were constructed by priori information of
cell-receptor, cell-ligand and receptors-ligand pairs from the FANTOM5 resource
(http://fantom.gsc.riken.jp/5/suppl/Ramilowski_et_al_2015/) (37). The TME cell types in
MCPcounter did not completely coincide with those in FANTOM5. The abundance of
endothelial cells and fibroblasts was calculated by MCPcounter algorithm for all types of
endothelial cells and fibroblasts in FANTOM5. Receptor ligand characteristics were defined as
intersection characteristics of endothelial cells and fibroblasts of FANTOM5, after removing
outlier cell types in FANTOM5 with low abundance by MCPcounter. Similar to Thorsson's
study (31), the edges in each TME subtype were determined in the scaffold of possible
interactions. Cell population, ligand and receptor gene expression values were divided into 3
parts (low, medium and high). If at least 66% of the samples in the subtype were mapped to
medium or high value of one node, this node was input into the subtype network. Only when
the 2 nodes consisting in the edge were in the network, can the edge and node be
incorporated into the network. Core subnetworks in different subtype networks were
determined by Molecular Complex Detection (MOCDE) method of Cytoscape (38).
Statistical analysis
All statistical analysis was implemented by R 3.5.1 (https://www.r-project.org/). R survival
package was used to cox proportional hazards regression. Receiver operating characteristic
curve (ROC) drawing and (area under curve) AUC calculation were based on pROC packages
(39). R stats package was used to Pearson correlation, variance analysis and chi square test.
P value less than 0.05 was considered statistically significant in all hypothesis tests. All the P
value were two-sided. The significance threshold of false discovery rate (FDR) q value was
also 0.05 in GO and KEGG enrichment analysis.
Results
The high-immune and low-stromal group and the low-immune and high-stromal group
were identified based on immune and stromal activity in TME
The Pearson correlation analysis of MCPcounter, CIBERSORT and TIMER showed the
greater difference between CIBERSORT and TIMER, and MCPcounter showed a higher
correlation with the other 2 tools (Supplementary Table S2). Therefore, data from MCPcounter
were used for subsequent analysis.
In NMF analysis, we confirmed 4 TME-related NMF factors with different immune and
stromal enrichment score as reported previously (Supplementary Fig. 2B) (9, 32). Interesting,
for univariate Cox regression, the significant positive relationship between NMF factor
expression feature and prognosis was in high-immune and low-stromal enrichment score
group (n = 35, P = 0.000144). Therefore, there were no significant effect in both double high (n
= 24, P = 0.721) and double low group (n = 31, P = 0.292). The low-immune and high-stromal
group showed adverse effects on OS (n = 12, P = 0.1524). The survival curves of high-immune
and low-stromal group versus the low-immune and high-stromal group were also different
(Figure 2C, HR = 0.5597458, P = 0.4776). The high-immune and low-stromal activity
expression pattern (NMF factor 6, Supplementary Fig. 2B) was identified. The enrichment
analysis of the exemplar genes (Top 100 weighted) in NMF factor 6 shows high immune
activity including humoral immune response (P = 1.37853438476176E-11, q-value = 1.05E-11),
T cell activation (P = 4.55E-10, q-value = 3.47E-10), response to IFN-γ (P = 4.82E-09, q-value
= 3.67E-09) and antigen processing and presentation of exogenous peptide antigen via MHC
class II (P = 9.02E-09, q-value = 6.87E-09, Supplementary Table S3, Supplementary Fig.
2D&E). In addition, significant stromal activation contained extracellular matrix organization (P
= 9.84E-62, q-value = 7.30E-62), collagen fibril organization (P = 9.84E-62, q-value =
7.30E-62), response to transforming growth factor beta (P = 9.84E-62, q-value = 7.30E-62,
Table S4, Supplementary Fig. 2F&G) for low-immune and high-stromal activity expression
pattern (NMF factor 5, Supplementary Fig. 2B).
Because the above TME-related NMF factors were low-dimensional and coarse-grained,
to further identify genes related to immune and stroma, we used MTL algorithm to screen
genes associated with 6 subtasks (feature of NMF factor 5, feature of NMF factor 6, T cell, B
cell, endothelial cell and fibroblast abundance of MCPcounter). The 179 immune and stroma
related genes were identified including many cluster of differentiation molecules and ligands
(CD1A, CD1B, CD1E, CD3G, CD8A, CD19, CD74, CD84, CD163, CD40LG, CD300LG), IFNG
(IFN-γ), VEGFA (vascular endothelial growth factor A), ITGB2 (integrin beta-2, CD18), major
histocompatibility complex molecule (HLA-DQA1, HLA-DPB1, HLA-DPA1, HLA-DRB1,
HLA-DRA, HLA-DQA2, HLA-B, HLA-C and HLA-A ), chemoattractants (CCL5, CCL19) and
collagen related genes (COL1A1, COL1A2, COL3A1, COL6A6, COL11A1 and COL29A1).
Consensus clustering (K = 2) of the above 179 genes successfully divided the patients into the
high immune-stromal ratio group and the low immune-stromal ratio group (Supplementary
Figure S3). DEGs were further analyzed between the above 2 groups (Supplementary Fig. S4,
Supplementary Table S5) for GSEA. Predictably, the high immune-stromal ratio group had
varied interleukin levels, IFN-γ production and adaptive immune activation, and the low
immune-stromal ratio group had higher oxidative phosphorylation, double-strand break repair
activation (P < 0.001, Supplementary Fig. S5, Supplementary Table S6).
Novel TME gene signatures and enrichment score
Novel TME gene signatures were optimized using DGE analysis for the high immune-stromal
ratio group versus the low immune-stromal ratio group. DGE analysis selected 166 DEGs with
P value less than 0.05 from the 179 immune and stromal characteristic genes (Supplementary
Table S7), and divide them into 2 categories (108 immunity-related category genes and 58
stroma-related category genes, Fig. 1A). Novel immune and stromal scores were calculated by
immunity-related and stroma-related genes. The new scores revealed higher relevance with
TME cells (Supplementary Fig. S6) and closer links to OS (immune score, beta = -1.7008, P =
0.0038; stromal score, beta = 7.245, P = 3.29e-05) than previous scores (Kosuke's immune
score, beta = -0.8936, P = 0.0276; Kosuke's stroma score, beta = -0.4914, P = 0.2833;
Richard's stroma score, beta = 0.6588, P = 0.0859) in Cox regression.
Cellular and molecular characteristics in the 4 TME groups based on immune and
stroma related gene features
Different immune and stromal activation divided the patients into the 4 categories (HL:
high-immune and low-stromal; LH: low-immune and high-stromal; HH: double high; LL: double
low). The 4 classifications were successfully achieved through the median value of the
immune and stromal scores. These 4 subtypes showed distinct TME-related gene expression
patterns (Fig. 1B).
Extensive hyperimmune cell infiltration and TIL were found in the hyperimmune class (P <
0.01, Fig. 2C). However, the high stromal activity group showed a large number of fibroblast
infiltration (P < 2.2e-16, Fig. 1C). To further understand the biological characteristics of the 4
subtypes at the whole mRNA levels, DGE analysis was used to identify high-expression gene
signatures of different classes (Fold change > 0, adjusted P-value < 0.05). In the HH group, T
cell activation (P = 0, q-value = 0.0010290), humoral immune response (P = 0, q-value =
0.00045020) and extracellular structure organization (P = 0, q-value = 0.0044475) were
exhibited in GSEA (Fig. 1D, Supplementary Table S8). There were significant enrichment in
the cytoskeleton, cell cycle regulation and DNA repair including microtubule cytoskeleton
organization involved in mitosis (P = 0, q-value = 5.33E-04) and double-strand break repair (P
= 0, q-value = 0.04247535) in the LH group (Fig. 1D, Supplementary Table S9). Significant
immune activation containing B cell activation (P = 0, q-value = 0), T cell activation (P = 0,
q-value = 0), interferon-gamma production (P = 0, q-value = 0.00517077) and interleukin-12
production (P = 0, q-value = 0.006059496, Fig. 1D, Supplementary Table S10) was observed
in the HL group. No significant enrichment was found in the LL group (q-value > 0.05). The
molecular characteristics of different immune and stromal class were shown in Fig. 1E.
Patients with high immune score were related to more activation in immune molecules, such
as IFN-y, IL-1, IL-2, IL-6, IL-10 (P < 2.2e-16). Besides, there was higher PD-1 activation in
patients with higher immune enrichment scores (P < 2.2e-16).
Six identified pan-cancer immune subtypes reported previously were integrated into our
novel classification (31). We found that 89.7% LUAD patients were identified as wound healing
(18.3%), IFN-γ dominant (31.7%) and inflammatory (39.7%) subtypes (Supplementary Table
S11). Significant higher proportion of wound healing subtypes was shown in the LH group
compared others (45.2% vs. 5.3%, P < 2.2e-16), suggesting high proliferation rate, high
expression of angiogenic genes and Th2 cell bias. HH group had high proportion of IFN-γ
dominant subtypes (59.7% vs. 26.3%, P = 5.311e-08) linked with high M1/M2 macrophage
polarization, CD8 signal (Fig. 1E). Inflammatory class had a larger number than other groups
in both HL and LL groups (66.0% vs. 54.2% vs. 16.5%, P < 2.2e-16), suggesting low to
moderate tumor cell proliferation, high Th17 and Th1 genes. Predictably, the 2 low immune
groups had more lymphocyte depleted subtype patients (7.0% vs. 1.4%, P = 0.006637) with
Th1 suppression and high M2 response.
Mutation Landscape and tumor mutation burden of different immune and stromal class
Mutation analysis was performed to gain the comprehensive perspective of genomic
characteristics though different immune and stromal class. Based on bi-classification method
(NMF consistency clustering for the above 166 TME characteristic genes), the high
immune-stromal ratio group showed a higher number of mutations (median patient mutations
225 vs. 115, P < 0.0001), higher tumor mutation burden (difference between means -3.049 ±
0.6019, P < 0.0001) and a higher mutation rate and Variant Allele Frequency (VAF) in the
driving genes (Supplementary Fig. S7 & 8, Fig. 2A-C). For instance, the low immune-stromal
ratio patients had high TP53 mutations (55% vs. 38%, P = 0.0002036) and more frame shift
deletion (13.46% vs. 8.60%, P = 0.341) and less nonsense mutation (16.03% vs. 22.58%, P =
0.2625). Similarly, higher mutation rate and VAF of KRAS (29% vs. 26%, 81 vs. 60, P = 0.518)
were observed in the same groups, and almost all mutations were missense. In the volcanic
map (Supplementary Table S12, Fig. 2D), we identified genes related to higher mutation
frequency and higher mutation rate difference between the high and low immune-stromal ratio
groups. In addition to TP53, COL11A1 and KEAP1 also showed a large rate difference
(COL11A1: rate difference = 14.55%, mutation frequency = 19.4%; KEAP1: rate difference =
10.82%, mutation frequency = 17.8%), and they had biological effects of extracellular matrix
organization and MHC-mediated antigen processing and presentation in Reactome pathways
database (40). The co-occurrence and mutually exclusive mutations were shown in Fig. 2E & F.
Moreover, higher mutation of WNT related genes was observed in the low immune-stromal
ratio groups (Supplementary Fig. S9 & 10).
For the 4 subgroups, significant lower TMB were found in the HH and LH groups (8.26243
vs. 4.98783, P = 5.637e-08, Fig. 2G). However, there was no significant difference between
the HH versus LH and HL versus LL groups (P of pairwise comparisons using t tests: 0.90422
and 0.79067). Actually, high stromal score showed the positive correlation with TMB (cor =
0.2935904, P= 1.619e-11, Fig. 2H). Moreover, there was a strong correlation between the
neoantigen of single nucleotide variation and TMB (cor = 0.9549101, P < 2.2e-16, Fig. 2I).
Weak negative correlation between immune score and TMB was found in this study (our
immune score: cor = -0.1369304, P= 0.002021; previous immune score: cor = -0.1068824, P=
0.01616).
The prognosis of different subtypes was significantly different
The clinical characteristics of the 4 groups were shown in the Table 1. Higher pathological
Tumor (T) stage was found in the low immune groups (P < 0.01), similar to pathological Node
(N) stage (P < 0.05) and pathological tumor stage (P < 0.01), suggesting a link between Tumor
Node Metastasis (TNM) stages and immune cell activity in TME.
Different TME subgroups showed significant different prognosis. Clinicopathological
information was used to obtain a more comprehensive perspective of prognostic factors for
both univariate and multivariate Cox regression analysis. Pathological T stage (β = 0.4153, P =
0.0115) and tumor status (β = 1.0658, P = 1.48e-05) were retained as significant prognostic
factors in multivariate Cox regression for backward selection. Both of TNM stages and residual
tumors were risk factors for OS (Table S13).
According to Cox regression analysis of TME relative cell contents in TCGA-LUAD cohort,
the positive effect of immune cells (T cells, B cells and myeloid dendritic cells) on prognosis
and the negative effect of stromal cells (fibroblasts) on prognosis were clarified
(Supplementary Table S14). The 2 grouping methods were implemented via consistency
clustering of 166 immune and stromal characteristic gene NMF algorithm (K = 2). The
dichotomy of LUAD (the high an low immune-stromal ratio groups) showed significant
prognostic differences of OS (HR = 0.5597458, P = 2e-04, Fig. 3A). For the 4 subgroups, HL
patients had significantly better OS than the others (HR = 0.4617451, P = 3.015633e-05, Fig.
3B). LH patients had worse OS (HR = 1.788947, P = 8.381535e-05), and HH and LL patients
were comparable (HR = 1.045836, P = 0.8443359), despite their distinct TME. The median
survival of the 4 groups had similar trend as OS (HL: 8.682192 years; HH: 4.194521 years; LL:
4.186301 years; LH: 2.857534 years).
Validation in Multidata Sets and Meta-Analysis
A total 1045 patients from 5 independent data sets with transcriptome and clinical data were
used to validate our classification methods on molecular characteristics and prognostic effects.
Higher immune score groups showed more immune mediator in all validation data sets (IFN-γ,
IL-1,2,6,10; P < 0.01, Supplementary Fig. S11-15). PD-1 activation was observed in high
immune groups (P < 0.01), except GSE68571 (P = 0.754). The abundance of different cell
population was comparable in GSE68571 (Supplementary Fig. S15), due to less mapping
genes (5545 genes vs. more than 13,000 genes in other data sets).
All data sets were used to validate the 166 TME characteristic genes used in our
bi-classification (the high an low immune-stromal ratio groups) of NMF consensus clustering.
Four data sets showed significant better OS in the high immune-stromal ratio group (P < 0.05),
and the 2 remaining data sets (GSE37745 and GSE68571) shared similar trend (Fig. 4A).
Meta-analysis were performed for OS in all 6 clinical cohorts for comprehensive analysis of the
different results. Because of low heterogeneity (tau^2 = 0, I^2 = 0.0% , P = 0.4673), fixed effect
model was selected for meta-analysis in bi-classification groups. The high immune-stroma
ratio group had significant better OS in meta-analysis (HR = 0.63, 95%CI: 0.54-0.73, Fig. 3C).
There was no obvious bias in all data sets according to linear regression test for funnel plot
asymmetry (P = 0.3014, Fig. 3D).
In multidata sets, univariate Cox regression revealed the positive prognostic significance
of immune score and the negative prognostic significance of stromal score (Table 2). Survival
analysis showed that HL group in the validation data sets also had better OS than other 3
groups, but the other subtypes were inconsistent in different data sets. (Fig. 4B).
Single-arm meta-analysis was utilized to evaluate the prognosis of the 4 subtypes for
3-year and 5-year survival. The HL group had the highest 3-year survival rate (0.81, 95%
CI:0.73-0.88, Fig. 3E-H), followed by the LL group (0.64, 95% CI: 0.55-0.74) and the other 2
groups (0.59, 95% CI: 0.53-0.66 for HH; 0.59, 95% CI: 0.54-0.64 for LL). Five-year survival
rate had similar trend with 3-year survival in all groups (0.66, 95% CI: 0.56-0.76 for HL; 0.51,
95% CI: 0.38-0.64 for LL; 0.48, 95% CI: 0.42-0.53 for LH; and 0.44, 95% CI: 0.37-0.52 for HH,
Fig. 3I-L).
PMBT Based on immune and stromal activition was Used to Predict Prognosis and
Immunetherapy Response
Because of the opposite predictive effect of the immune and stromal scores on prognosis, we
attempted to develop a prognostic evaluation equation that integrated these 2 scores based on
Cox model:
Score of Prognostic Model Based on TME (PMBT) = -1.0635 × immune score + 6.4067 ×
stromal score
The related code of PMBT was encapsulated as a R package (GitHub website:
https://github.com/ZengZihang/PMBT). The manual of PMBT package was available at NAR
online. The PMBT score was significantly related to OS (Table 2). The median PMBT of each
data sets was used as the threshold in this study. Clearly, PMBT showed significant prognostic
value for OS in 5 data sets except GSE37745 (P = 0.334, Supplementary Fig. 16A).
Comparing with existing prognostic methods for LUAD, PMBT scores of 3,5-year survival were
related to wider areas under the curve than other TME-based indexes, including T cells, B cells,
fibroblasts, PD1 signaling, IFN-γ and previous immune and stroma enrichment scores
(Supplementary Fig. 16B).
Our novel PMBT was used to predict anti-CTLA-4 and anti-PD-1 response in melanoma
immunotherapy data set (41). The immune score of overall immune response (neglect of
therapeutic drugs) was positively correlated to the immunotherapy effects (P < 0.05,
Supplementary Table 15). On the other hand, PMBT score was negatively correlated to the
immunotherapy effects (P < 0.05, Supplementary Table 15). While none of the 3 scores was
correlated with anti-CTLA-4 treatment (P > 0.05, Supplementary Table 15), all the 3 scores of
anti-PD-1 therapy showed a better predictive effect in correlation analysis (all, P < 0.05) and
ROC than those of overall treatment. The PMBT and immune scores had better prediction
values than the stromal score (Supplementary Table 15).
Intercellular Communication Networks in TME
In the TME, a wide range of signal transmission between cell types occurs through the soluble
proteins and direct communication. Intercellular communication networks were constructed
using the prior information about cell ligands and receptors, as well as TCGA data.
For all LUAD patients, the subnetwork containing CD8+ T cells, B cells, NK cells and
fibroblasts was identified by Molecular Complex Detection (MOCDE) method (Fig. 5A). In this
subnetwork, the interactions of ligands and receptors in immune cells and fibroblasts were
mediated by collagens (COL1A1 and COL1A2), integrin subunits (ITGAL, ITGA1, ITGA2,
ITGA4, ITGA5 and ITGA6), C-X-C motif chemokine receptors (CXCR1, CXCR2 and CXCR3)
and TNF superfamily members (TNF, TNFSF13 and TNFRSF1A).
Different subnetworks were identified in different subgroups. Both stroma-centered
subnetworks (fibroblasts, endothelial cells and laminin, Fig. 5B) and immunity-centered (CD8+
T cells, B cells, CD molecule, interleukin receptors and TNF superfamily members, Fig. 5C)
were identified in the HH group. No stroma-centered and 2 immunity-centered subnetworks
were identified in the HL group. One was cellular immune subnetwork consisting of CD4+ T
cells, CD8+ T cells, NK cells, dendritic monocyte, CD molecules, C-C motif chemokine ligands
and HLA-A (Fig. 5D), and the other was humoral immune subnetwork containing B cells,
neutrophils, macrophage monocyte, Class I major histocompatibility complex (HLA-B, HLA-C
and HLA-G), leukocyte immunoglobulin-like receptors and C-C motif chemokine receptors (Fig.
5E). These results suggested that C-C motif chemokine mediated the communication of
cellular and humoral immune in high immunoreactive subtypes absent of stromal activation.
Contrarily, in the LH group, only fibroblast-centered subnetwork containing ITGB4, LAMB1,
LAMB3 and LAMC1 was identified in the LH group (Fig. 5F). No subnetwork with more than 5
nodes was identified in the LL group, suggesting its desert-like molecular communication. Our
results indicated that the 4 TME groups classified by PMBT had different molecular and
cellular characteristics, as well as excellent predictive effects on prognosis and
immunotherapy response in LUAD patients.
Discussion
TME played an important role in tumorigenesis and development. However, the landscape of
TME, especially immune and stromal cell infiltration on LUAD remained to be fully elucidated.
Our study suggested more comprehensive understanding by considering both immune and
stromal activity simultaneously. Virtual dissection of mixed tumor tissues was realized by
signal decomposition algorithm NMF. Through the NMF, as well as other bioinformatics and
machine learning methods, we successfully identified the genetic characteristics of immunity
and stroma in LUAD. Based on the 167 TME related genes, we classified LUAD into 4
subtypes with different molecular, cellular and prognostic characteristics.
Although the immune checkpoint inhibitor (anti-PD-1/PD-L1) treatment benefited NSCLC
patients (42-44), only about ~16% patients had long-term survival under immunotherapy (6,
45). Screening of potentially sensitive population for immunotherapy helped to decrease
medical expenses and improve quality of life. By calculating our immune , stromal and PMBT
scores, we found that there was a significantly positive correlation between immune scores
and immune response rates in anti-PD-1 therapy (P = 0.022), but negative correlation with the
stromal scores (P = 0.039) and PMBT scores (P = 0.021). In conclusion, our PMBT was
beneficial to predict the response and prognosis of immunotherapy.
TMB have complex effects on tumorigenesis (46). Driver mutations, such as tumor
suppressor gene TP53, may increase genomic instability and increase cell proliferation, which
may link to unfavorable prognosis (47, 48). On the other hand, passenger mutations may
activate the immune responses through the production of neoantigens and thus contribute to
prognosis and immunotherapy response. Recent clinical studies revealed significantly different,
even opposite, prognostic effect of TMB in NSCLC patients without immunotherapy. In
LACE-Bio-II (LB2) study (49), high TMB group (≥ 8 m/Mb) had better disease free survival
(DFS), OS and lung cancer specific survival (LCSS) in 908 NSCLC patients after complete
resection with targeted sequencing of 1538 genes, while the low TMB group (< 4 m/Mb) had
worse prognosis (DFS: P = 0.007; OS: P = 0.016; LCSS: P = 0.001). However, another clinical
study indicated that higher TMB (≥ 62 m/Mb) correlated with worse OS in 90 NSCLC patients
only underwent surgery (HR = 6.633, P = 0.0003) (50). TMB was also found to be a poor
prognostic factor in multivariate Cox regression (HR = 12.31, P = 0.019) in all stages,
especially in stage I NSCLC patients (OS: HR = 7.582, P = 0.0018; DFS: HR = 6.07, P =
0.0072). TMB may not be a very robust prognostic marker due to lack of elaborate
consideration of the biological effects of individual mutation, driver and passenger mutations,
as well as the interference of TME RNAs when sequencing. In our study, the HH and LH
groups had significantly higher TMB (Fig. 2G), suggesting TMB was directly or indirectly
related with stromal activation, in addition to the scores of immune activation. Patients with low
stromal activation had less TMB (Fig. 2H). The prediction values of TMB and its relationship
with TME remain to be studied. Single-cell whole exome sequencing may provide new insights
due to higher purity of the tumor samples.
In intercellular communication network, fibroblast-centered networks were identified in the
HH and LH groups, suggesting that fibroblasts mediated stromal activation by specific laminin
(LAMA2, LAMB1, LAMB3, LAMC1) and collagens (COL1A2, COL18A1, Fig. 5B & F). In
addition to cellular immune related network, humoral immune related cells and molecules (Fig.
5D) were also identified in the HH and HL groups, suggesting that the humoral immune
network also had value of cell communication in TME.
Overall, we identified both the immune- and stromal-related gene signatures in LUAD and
classified the tumor tissues into 4 groups according to the TME rather than the tumor itself.
PMBT was constructed by integrating both immune and stromal scores. PMBT showed
excellent value to predict the prognosis and immune response. We expected PMBT score to
be validated in more data sets to determine the thresholds. In this study, only lung cancer data
were used for analysis. Our results need to be further validated and carefully used in
pan-cancer.
Availability
MCPcounter is an open source R package (https://zenodo.org/record/61372).
CIBERSORT is a free tool developed by Newman et al (http://cibersort.stanford.edu).
TIMER is an open source software in website (https://cistrome.shinyapps.io/timer/)
MALSAR is an open source matlab tool (https://github.com/jiayuzhou/MALSAR).
Cytoscape is an open source software platform for visualizing complex networks and
integrating these with any type of attribute data (https://cytoscape.org).
RevMan 5 is the software used for preparing and maintaining Cochrane Reviews
(https://community.cochrane.org/help/tools-and-software/revman-5/revman-5-download).
WebGestalt is an open tool (http://www.webgestalt.org/option.php).
PMBT is an R package used for data preprocessing, standardization and calculation of
immune,stromal, PMBT scores (https://github.com/ZengZihang/PMBT).
Other R packages can be loaded in CRAN (comprehensive r archive network,
https://cran.r-project.org) or Biocounductor (http://bioconductor.org).
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Tables
Table 1
Variable
High-immune and
high stromal-group
(n=91)
High-immune and
low-stromal group
(n=162)
Low-immune and
high-stromal group
(n=162)
Low immune and
low-stromal group
(n=91)
P-value
Gender 0.5812
Male 37 (40.7) 74 (45.7%) 80 (49.4%) 44 (48.4%)
Female 54 (59.3) 88 (54.3%) 82 (50.6%) 47 (51.6%)
Median age
(IQR)
66.5 (57.7-72.2) 69.4 (62.7-75.0) 63.3 (56.2-71.6) 65.3 (60.5-72.0) <0.001
Mean
smoking
years (IQR)
2.89 (2-4) 2.84 (2-4) 2.82 (2-4) 2.65 (2-4) 0.489
Pathologic
T
0.009267
T1-2 84 (92.3%) 147 (91.9%) 135 (83.3%) 72 (80.0%)
T3-4 7 (7.7%) 13 (8.1%) 27 (16.6%) 18 (20.0%)
Pathologic
N
0.02856
N0-1 76 (84.4%) 142 (91.6%) 127 (79.9%) 74 (82.2%)
N2-3 14 (15.6%) 13 (8.4%) 32 (20.1%) 16 (17.8%)
Pathologic
M
0.4085
M0 59 (93.7) 109 (94.8%) 110 (94.0%) 61 (88.4%)
M1 4 (6.3%) 6 (5.2%) 7 (6.0%) 8 (11.6%)
Pathologic
stage
0.008491
Stage I-II 71 (78.9%) 137 (86.7%) 119 (74.4%) 63 (70.0%)
Stage III-IV 19 (21.1%) 21 (13.3%) 41 (25.6%) 27 (30.0%)
Tumor
status
0.004681
Tumor free 52 (69.3%) 112 (83.0%) 92 (73.0%) 45 (60.8%)
With tumor 23 (30.7%) 23 (17.0%) 34 (27.0%) 29 (39.2%)
Residual
tumor
0.1793
R0 59 (92.2%) 106 (98.1%) 116 (95.9%) 62 (92.5%)
R1-2 5 (7.8%) 2 (1.9%) 5 (4.1%) 5 (7.5%)
Table 2
Datasets
Immune score Stroma score PRTM score
coef P coef P coef P
TCGA -1.7008 0.0038 7.245 3.29E-05 1 7.28E-06
GSE11969 -3.005 0.0178 2.9082 0.00142 0.4448 0.00101
GSE68465 -0.6216 0.23 3.896 0.0165 0.4804 0.0167
GSE68571 -3.07133 0.0295 1.39E+01 0.00595 2.0835 0.00185
GSE37745 -1.2924 0.0605 0.6 0.753 0.2422 0.334
GSE50081 -0.9187 0.39 10.641 0.000462 1.2122 0.00138
Figures
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Table and figure legends
Table 1. Clinical information table for four subtypes.
Table 2. Univariate Cox regression of immune, stroma and PMBT scores.
Figure 1. Cellular and molecular characteristics in the 4 TME groups based on immune and
stroma related gene features. (A) Volcano map of optimized immune and stroma related genes;
(B) Heatmap of immune and stroma related genes in the 4 TME groups; (C) Heatmap for
cellular characteristics in the 4TME groups; (D) GSEA of the 4 TME groups; (E) Box diagram
of cellular and molecular characteristics in the 4 TME groups. The HH meant high-immune and
high-stromal group. The HL meant high-immune and low-stromal group. The LH meant
low-immune and high-stromal group. The LL meant low-immune and low-stromal group.
Figure 2. The low-immune and high-stromal group had higher driving gene mutation rate and
TMB than the high-immune and low-stromal group. (A) Mutation landscape of the
high-immune and low-stromal group; (B) Mutation landscape of the low-immune and
high-stromal group; (C) forest map of mutation between the high-immune and low-stromal
group and the low-immune and high-stromal group; (D) Volcano map of mutation rate between
the high-immune and low-stromal group and the low-immune and high-stroma group; (E)
Co-occurance and exclusive mutation in the high-immune and low-stromal group; (F)
Co-occurance and exclusive mutation in the low-immune and high-stromal group; (G) Box
diagram of TMB in the 4 subtypes; (H) Scatter plot between TMB and stromal scores; (I)
Scatter plot between TMB and numbers of new antigens. The HH meant high-immune and
high-stromal group. The HL meant high-immune and low-stromal group. The LH meant
low-immune and high-stromal group. The LL meant low-immune and low-stromal group.
Figure 3. The high-immune and low-stromal group had better survival than other groups. (A)
Survival curves of the 4 TME subgroups by ssGSEA; (B) Survival curves of the high and low
immune-stroma ratio groups by NMF consensus clustering; (C) Meta-analysis of OS in training
and validation data sets; (D) Funnel plot of OS meta-analysis; (E-H) Meta-analysis of 3-year
survival rate in the HH, HL, LH and LL groups; (I-L) Meta-analysis of 5-year survival rate in the
HH, HL ,LH and LL groups. The HH meant high-immune and high-stromal group. The HL
meant high-immune and low-stromal group. The LH meant low-immune and high-stromal
group. The LL meant low-immune and low-stromal group.
Figure 4. OS of the 5 validation data sets. (A) Survival curves of the high and low
immune-stromal ratio groups; (B) Survival curves of the 4 groups.
Figure 5: (A) Core subnetwork of all patients; (B,C) Core subnetworks of high-immune and
high-stromal group; (D,E) Core subnetworks of high-immune and low-stromal group; (F) Core
subnetwork of the low-immune and high-stromal group
